Publication
CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.
Marie José Kersten, Maria T Kuipers, Pim G N J Mutsaers, Evelyne Willems, Kirsten Saevels, Martin Dreyling, Caron Jacobson, Michael R Bishop, Maarten Zandvliet, Stavros Milatos, Chiara Lobetti-Bodoni, Sandra Blum, Kirsten Van Hoorde, Jigar Desai, Lorenzo Acciarri, Margot J Pont, Anna van Muyden, Omotayo Fasan, Joost S P Vermaat, Sébastien Anguille
- Source
- PubMed
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260917-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell non-Hodgkin lymphoma, but centralised manufacturing-with its complex logistics and long vein-to-vein times-drives up costs and restricts access. We aimed to evaluate the safety of GLPG5101, a…
Read on PubMedLinked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT06561425registry_reference1.00
Candidate 2
- cancerHodgkin Lymphomadictionary0.60
- cancerNon-Hodgkin Lymphomadictionary0.60
Registered trialsNCT06561425
Curated evidence
Evidence citing this paper (0)
Data not yet available